Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000708631 | SCV000821788 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-01-01 | criteria provided, single submitter | clinical testing | This variant is a single amino acid change from Glutamate to a premature translational stop signal at codon 94 of the VHL protein. This is expected to result in an absent or disrupted protein product.. This variant has been described in the international literature in an individual undergoing panel testing for hereditary syndrome (PMID: 31159747). The mutation database ClinVar contains entries for this variant (Variation ID: 584477). |
Genomic Diagnostic Laboratory, |
RCV000767251 | SCV000897798 | pathogenic | Von Hippel-Lindau syndrome | 2018-08-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001222557 | SCV001394661 | pathogenic | Chuvash polycythemia; Von Hippel-Lindau syndrome | 2019-04-08 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in VHL are known to be pathogenic (PMID: 8956040, 12202531). This variant has been observed in several individuals and  families affected with von Hippel-Lindau syndrome (PMID: 7987306, 12000816, 12624160, 22357542). This variant is also known as 493G>T and Glu165Ter in the literature. ClinVar contains an entry for this variant (Variation ID: 584477). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Glu94*) in the VHL gene. It is expected to result in an absent or disrupted protein product. |